The HHS announcement offers a potentially useful treatment route for a narrow group of children while also advancing a pregnancy-medication warning built on conflicting evidence. That combination has put scientific certainty, clinical judgment and family expectations at the center of the policy fight.
Robert F. Kennedy Jr. has released a new autism plan with President Donald Trump and the U.S. Department of Health and Human Services in Washington, D.C. The September 22, 2025 announcement pairs a proposed treatment pathway for leucovorin with a warning campaign around acetaminophen, the drug sold as Tylenol, while pledging new research for autistic people and their families.
The plan’s scientific basis and expected impact vary sharply by piece. HHS said autism has risen nearly 400% since 2000 and now affects 1 in 31 American children, but it also acknowledged conflicting research and no clear causal evidence on the pregnancy-acetaminophen question driving its most contentious action.
Three policies under one banner
The announcement is best understood as three separate federal moves rather than one settled medical strategy. The first concerns leucovorin, a prescription form of folate that HHS says may help some children who have cerebral folate deficiency and autistic symptoms, particularly with speech-related deficits.
FDA was to publish a Federal Register notice outlining a label update for leucovorin in cerebral folate deficiency. HHS said the change would establish an FDA-recognized therapeutic pathway and could allow state Medicaid programs to cover the drug for an autism-related indication in coordination with the Centers for Medicare & Medicaid Services.
The second move is an FDA physician notice and a process to pursue a safety-label change for acetaminophen. HHS also said it would mount a public-service campaign about use of the medication for fever and pain during pregnancy.
Third, the National Institutes of Health announced 13 Autism Data Science Initiative projects totaling more than $50 million. Those projects are intended to combine biological, clinical and behavioral data with research into environmental, nutritional, medical, social and genetic factors.
Leucovorin is not an autism cure
The treatment portion of the announcement may be the most concrete immediate change for families, but HHS itself placed major limits around it. The agency said leucovorin is not a cure for autism and may improve speech-related deficits only for a subset of children.
That distinction matters because autism is a spectrum, not a single condition with one uniform treatment response. A child’s individual medical history, possible folate-related issues, current therapies and clinician’s assessment would all matter before a prescription decision.
HHS said use should occur under close medical supervision and alongside non-drug approaches, including behavioral therapy. NIH is expected to conduct confirmatory trials and safety studies, which means important questions about which patients benefit, by how much and under what conditions are still being studied.
For supporters, opening a coverage and prescribing pathway could remove a barrier for families whose children may be candidates. For critics, presenting an early or limited-use treatment within a broad autism initiative risks creating expectations that run ahead of the evidence and the drug’s narrowly described role.
The Tylenol claim carries the tension
The acetaminophen initiative is where the plan’s language becomes most consequential—and most unsettled. HHS said prior clinical and laboratory studies suggest a potential association between acetaminophen use in pregnancy and adverse neurodevelopmental outcomes.
But the same HHS announcement says there are contrary studies showing no association, and that the literature lacks clear causal evidence. An association in research does not, on its own, show that one factor caused another outcome; that gap is especially important when a common medication is involved.
HHS also noted that untreated fever during pregnancy can carry risks for both the pregnant patient and fetus. It said acetaminophen is often the only available tool for pain and fever because alternatives such as NSAIDs have well-established adverse effects in pregnancy.
The agency’s practical advice was for clinicians to use their judgment and prescribe the lowest effective dose for the shortest necessary duration when treatment is needed. That is notably more cautious than an implication that patients should avoid the medicine outright.
Why families may hear mixed messages
Families looking for services, reliable medical care and better support may welcome a larger federal research commitment. The NIH projects include work across childhood and adulthood, replication hubs intended to test findings, and community engagement meant to reflect the needs of autistic people, families and clinicians.
Still, the initiative uses the language of an “autism epidemic” and emphasizes finding “root causes.” Some advocates and researchers may see that framing as too focused on autism as a condition to be eliminated, rather than on supports, autonomy, communication access and quality of life for autistic people.
The HHS release does not lay out new nationwide commitments on areas many families confront daily, such as school supports, adult housing, employment, caregiver respite, insurance obstacles or long waits for diagnostic and specialty care. Research funding can build future knowledge, but it does not automatically solve those access problems.
That gap helps explain why the initiative can land differently with different audiences. A family seeking a possible treatment for a specific speech-related issue may see an opening; another may see a policy package that places disputed causation claims ahead of the services autistic people need now.
What the announcement actually settles
The September 22 announcement does not establish that acetaminophen causes autism, and HHS did not say it had done so. It announces a warning process, a public-information campaign and further research in the face of conflicting findings.
It also does not establish leucovorin as a general treatment for autism. The federal description is narrower: a possible option for children with cerebral folate deficiency and autistic symptoms, with continued use tied to observed language, social or adaptive gains.
The most durable part of the plan may be its investment in data and follow-up studies. Whether that work improves care will depend on transparent methods, replication, clinically meaningful results and whether future policy addresses services as well as causes and medications.
For now, the key takeaway is that Kennedy’s initiative contains one potentially targeted treatment avenue, one scientifically disputed medication warning and a significant research investment. Treating those components as if they carry the same level of certainty would obscure the choices families and clinicians still have to make together.
Leave a Reply